SIMILAR PATTERNS OF AMINO ACIDS FOR 4WA9_B_AXIB9000

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 416 ALA A 428 LYS A 430 THR A 474 MET A 477 GLY A 480 LEU A 528	None	0.79A	4wa9B-1k2pA: 31.4	4wa9B-1k2pA: 45.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 416 ALA A 428 THR A 474 MET A 477 GLY A 480 ASN A 526 LEU A 528	None	0.81A	4wa9B-1k2pA: 31.4	4wa9B-1k2pA: 45.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	VAL A 209 ALA A 220 LYS A 222 THR A 266 MET A 269 GLY A 272 LEU A 321	None	0.72A	4wa9B-1k9aA: 32.2	4wa9B-1k9aA: 29.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	VAL A 209 ALA A 220 THR A 266 MET A 269 GLY A 272 ASN A 319 LEU A 321	None	0.60A	4wa9B-1k9aA: 32.2	4wa9B-1k9aA: 29.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1luf	MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK (Rattus norvegicus)	PF07714 (Pkinase_Tyr)	8	VAL A 588 ALA A 606 LYS A 608 MET A 657 GLY A 660 ASN A 729 LEU A 731 ALA A 741	None	0.58A	4wa9B-1lufA: 32.4	4wa9B-1lufA: 36.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	TYR A 272 VAL A 275 ALA A 288 THR A 334 MET A 337 GLY A 340 LEU A 389 ALA A 399	P16 A 2 (-3.6A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-3.7A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.79A	4wa9B-1opkA: 37.8	4wa9B-1opkA: 57.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	10	VAL A 275 ALA A 288 LYS A 290 THR A 334 PHE A 336 MET A 337 GLY A 340 ASN A 387 LEU A 389 ALA A 399	P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) None P16 A 2 (-3.4A) None P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.54A	4wa9B-1opkA: 37.8	4wa9B-1opkA: 57.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ac5	MAP KINASE-INTERACTING SERINE/THREONINE KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 98 ALA A 111 LYS A 113 MET A 162 GLY A 165 ASN A 210 LEU A 212	None	0.75A	4wa9B-2ac5A: 20.4	4wa9B-2ac5A: 24.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2buj	SERINE/THREONINE-PRO TEIN KINASE 16 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 34 ALA A 47 LYS A 49 PHE A 100 GLY A 104 ASN A 153 LEU A 155	STU A1301 (-4.8A) STU A1301 (-3.6A) STU A1301 ( 4.0A) STU A1301 (-4.5A) STU A1301 ( 4.0A) None STU A1301 ( 4.8A)	0.71A	4wa9B-2bujA: 24.2	4wa9B-2bujA: 23.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL X 25 ALA X 37 LYS X 39 THR X 82 MET X 85 GLY X 88 LEU X 137 ALA X 147	STU X 902 ( 4.8A) STU X 902 (-3.1A) STU X 902 (-3.1A) STU X 902 (-4.1A) None STU X 902 (-3.5A) STU X 902 (-4.4A) STU X 902 ( 4.1A)	0.71A	4wa9B-2dq7X: 35.4	4wa9B-2dq7X: 45.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL X 25 ALA X 37 THR X 82 MET X 85 GLY X 88 ASN X 135 LEU X 137 ALA X 147	STU X 902 ( 4.8A) STU X 902 (-3.1A) STU X 902 (-4.1A) None STU X 902 (-3.5A) STU X 902 ( 4.9A) STU X 902 (-4.4A) STU X 902 ( 4.1A)	0.50A	4wa9B-2dq7X: 35.4	4wa9B-2dq7X: 45.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	VAL A 281 ALA A 293 THR A 338 MET A 341 GLY A 344 ASN A 391 LEU A 393 ALA A 403	H8H A 534 (-4.4A) H8H A 534 (-3.2A) H8H A 534 (-3.1A) None H8H A 534 (-3.3A) H8H A 534 ( 4.9A) H8H A 534 (-4.5A) H8H A 534 ( 4.0A)	0.80A	4wa9B-2h8hA: 30.4	4wa9B-2h8hA: 27.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	ALA A 293 THR A 338 PHE A 340 MET A 341 GLY A 344 ASN A 391 LEU A 393 ALA A 403	QUE A 1 (-3.5A) QUE A 1 (-3.3A) QUE A 1 (-4.2A) None QUE A 1 (-3.0A) None QUE A 1 (-4.4A) QUE A 1 ( 4.5A)	0.58A	4wa9B-2hckA: 30.4	4wa9B-2hckA: 33.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	VAL A 281 ALA A 293 LYS A 295 THR A 338 PHE A 340 MET A 341 LEU A 393 ALA A 403	QUE A 1 ( 4.8A) QUE A 1 (-3.5A) None QUE A 1 (-3.3A) QUE A 1 (-4.2A) None QUE A 1 (-4.4A) QUE A 1 ( 4.5A)	1.17A	4wa9B-2hckA: 30.4	4wa9B-2hckA: 33.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	VAL A 281 ALA A 293 THR A 338 PHE A 340 MET A 341 ASN A 391 LEU A 393 ALA A 403	QUE A 1 ( 4.8A) QUE A 1 (-3.5A) QUE A 1 (-3.3A) QUE A 1 (-4.2A) None None QUE A 1 (-4.4A) QUE A 1 ( 4.5A)	0.85A	4wa9B-2hckA: 30.4	4wa9B-2hckA: 33.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hen	EPHRIN TYPE-B RECEPTOR 2 (Mus musculus)	PF07714 (Pkinase_Tyr)	7	VAL A 643 ALA A 659 THR A 707 MET A 710 GLY A 713 ASN A 759 LEU A 761	ADP A 400 ( 4.4A) ADP A 400 (-3.2A) ADP A 400 (-4.7A) None ADP A 400 ( 4.2A) MG A 404 (-4.5A) ADP A 400 ( 4.7A)	0.92A	4wa9B-2henA: 31.4	4wa9B-2henA: 39.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hen	EPHRIN TYPE-B RECEPTOR 2 (Mus musculus)	PF07714 (Pkinase_Tyr)	7	VAL A 643 ALA A 659 THR A 707 PHE A 709 MET A 710 GLY A 713 LEU A 761	ADP A 400 ( 4.4A) ADP A 400 (-3.2A) ADP A 400 (-4.7A) None None ADP A 400 ( 4.2A) ADP A 400 ( 4.7A)	0.72A	4wa9B-2henA: 31.4	4wa9B-2henA: 39.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	VAL A 259 ALA A 271 LYS A 273 THR A 316 PHE A 318 MET A 319 GLY A 322 LEU A 371 ALA A 381	1BM A 499 ( 4.8A) 1BM A 499 (-3.6A) 1BM A 499 (-3.8A) 1BM A 499 (-3.2A) 1BM A 499 (-4.1A) None 1BM A 499 (-3.5A) 1BM A 499 (-4.4A) 1BM A 499 ( 3.7A)	0.79A	4wa9B-2hk5A: 35.2	4wa9B-2hk5A: 46.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	VAL A 259 ALA A 271 THR A 316 PHE A 318 MET A 319 GLY A 322 ASN A 369 LEU A 371 ALA A 381	1BM A 499 ( 4.8A) 1BM A 499 (-3.6A) 1BM A 499 (-3.2A) 1BM A 499 (-4.1A) None 1BM A 499 (-3.5A) 1BM A 499 (-4.1A) 1BM A 499 (-4.4A) 1BM A 499 ( 3.7A)	0.69A	4wa9B-2hk5A: 35.2	4wa9B-2hk5A: 46.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	VAL A 256 ALA A 269 LYS A 271 THR A 315 PHE A 317 MET A 318 GLY A 321 LEU A 370 ALA A 380	GIN A 600 ( 4.7A) GIN A 600 (-3.1A) GIN A 600 (-3.6A) GIN A 600 (-3.4A) GIN A 600 (-4.3A) None None GIN A 600 (-4.7A) GIN A 600 (-3.1A)	0.63A	4wa9B-2hz0A: 34.9	4wa9B-2hz0A: 99.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	VAL A 256 ALA A 269 THR A 315 PHE A 317 MET A 318 GLY A 321 ASN A 368 LEU A 370 ALA A 380	GIN A 600 ( 4.7A) GIN A 600 (-3.1A) GIN A 600 (-3.4A) GIN A 600 (-4.3A) None None None GIN A 600 (-4.7A) GIN A 600 (-3.1A)	0.64A	4wa9B-2hz0A: 34.9	4wa9B-2hz0A: 99.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 259 ALA A 271 LYS A 273 THR A 316 MET A 319 GLY A 322 LEU A 371 ALA A 381	None 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.3A) 1N8 A 501 ( 4.4A) 1N8 A 501 ( 3.5A) 1N8 A 501 ( 4.3A) 1N8 A 501 ( 3.3A)	0.78A	4wa9B-2og8A: 31.4	4wa9B-2og8A: 45.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 259 ALA A 271 THR A 316 MET A 319 GLY A 322 ASN A 369 LEU A 371 ALA A 381	None 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.3A) 1N8 A 501 ( 4.4A) 1N8 A 501 ( 3.5A) None 1N8 A 501 ( 4.3A) 1N8 A 501 ( 3.3A)	0.70A	4wa9B-2og8A: 31.4	4wa9B-2og8A: 45.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qlu	ACTIVIN RECEPTOR TYPE IIB (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 204 ALA A 215 LYS A 217 THR A 265 PHE A 267 LEU A 328 ALA A 338	ADE A 488 ( 4.9A) ADE A 488 (-3.2A) None ADE A 488 (-4.3A) ADE A 488 (-4.3A) ADE A 488 (-4.4A) None	0.96A	4wa9B-2qluA: 26.2	4wa9B-2qluA: 25.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qlu	ACTIVIN RECEPTOR TYPE IIB (Homo sapiens)	PF00069 (Pkinase)	8	VAL A 204 ALA A 215 THR A 265 PHE A 267 GLY A 271 ASN A 326 LEU A 328 ALA A 338	ADE A 488 ( 4.9A) ADE A 488 (-3.2A) ADE A 488 (-4.3A) ADE A 488 (-4.3A) ADE A 488 ( 4.1A) None ADE A 488 (-4.4A) None	0.74A	4wa9B-2qluA: 26.2	4wa9B-2qluA: 25.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2qob	EPHRIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 635 ALA A 651 THR A 699 MET A 702 GLY A 705 ASN A 751 LEU A 753	BME A 1 (-4.9A) PTR A 701 ( 4.7A) None PTR A 701 ( 3.5A) None None None	0.77A	4wa9B-2qobA: 32.1	4wa9B-2qobA: 34.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r2p	EPHRIN TYPE-A RECEPTOR 5 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	VAL A 689 ALA A 705 THR A 753 MET A 756 GLY A 759 ASN A 805 LEU A 807	None	0.58A	4wa9B-2r2pA: 34.8	4wa9B-2r2pA: 37.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xik	SERINE/THREONINE PROTEIN KINASE 25 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 34 ALA A 47 LYS A 49 GLY A 101 ASN A 145 LEU A 147 ALA A 157	J60 A1294 ( 4.9A) J60 A1294 (-3.3A) None J60 A1294 ( 3.8A) None J60 A1294 (-4.8A) J60 A1294 ( 4.2A)	0.98A	4wa9B-2xikA: 20.5	4wa9B-2xikA: 27.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2xyu	EPHRIN TYPE-A RECEPTOR 4, (Mus musculus)	PF07714 (Pkinase_Tyr)	8	VAL A 635 ALA A 651 LYS A 653 THR A 699 MET A 702 GLY A 705 ASN A 751 LEU A 753	Q9G A1898 ( 4.7A) Q9G A1898 (-3.2A) Q9G A1898 (-4.8A) Q9G A1898 (-3.5A) None Q9G A1898 ( 3.8A) None Q9G A1898 (-4.3A)	0.77A	4wa9B-2xyuA: 32.4	4wa9B-2xyuA: 38.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2y7j	PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 38 ALA A 51 LYS A 53 MET A 110 GLY A 113 ASN A 158 LEU A 160	None B49 A1294 (-3.2A) None None B49 A1294 (-3.6A) None B49 A1294 (-4.4A)	0.90A	4wa9B-2y7jA: 25.4	4wa9B-2y7jA: 26.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	7	VAL A 261 ALA A 273 LYS A 275 THR A 319 PHE A 321 MET A 322 ALA A 384	None	0.84A	4wa9B-2zv7A: 32.6	4wa9B-2zv7A: 45.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	9	VAL A 261 ALA A 273 THR A 319 PHE A 321 MET A 322 GLY A 325 ASN A 372 LEU A 374 ALA A 384	None	0.81A	4wa9B-2zv7A: 32.6	4wa9B-2zv7A: 45.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 495 ALA A 515 LYS A 517 GLY A 570 ASN A 631 LEU A 633 ALA A 643	M33 A1996 ( 4.7A) M33 A1996 (-3.3A) M33 A1996 ( 4.5A) M33 A1996 ( 4.8A) None M33 A1996 (-4.5A) None	0.86A	4wa9B-3b2tA: 33.4	4wa9B-3b2tA: 40.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3c0i	PERIPHERAL PLASMA MEMBRANE PROTEIN CASK (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 26 ALA A 39 LYS A 41 PHE A 93 MET A 94 GLY A 96 LEU A 148	3AM A 338 ( 4.1A) 3AM A 338 (-3.3A) 3AM A 338 (-2.9A) 3AM A 338 ( 4.6A) None None 3AM A 338 (-4.7A)	0.89A	4wa9B-3c0iA: 25.5	4wa9B-3c0iA: 25.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 209 ALA A 220 LYS A 222 THR A 266 MET A 269 GLY A 272 LEU A 321	None	0.72A	4wa9B-3d7uA: 27.5	4wa9B-3d7uA: 44.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 209 ALA A 220 THR A 266 MET A 269 GLY A 272 ASN A 319 LEU A 321	None	0.60A	4wa9B-3d7uA: 27.5	4wa9B-3d7uA: 44.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3dko	EPHRIN TYPE-A RECEPTOR 7 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	8	VAL A 647 ALA A 663 LYS A 665 PHE A 713 MET A 714 GLY A 717 ASN A 763 LEU A 765	IHZ A1001 ( 4.4A) IHZ A1001 (-3.3A) IHZ A1001 ( 4.5A) None None IHZ A1001 ( 3.9A) None IHZ A1001 (-4.6A)	0.92A	4wa9B-3dkoA: 30.7	4wa9B-3dkoA: 36.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3dtc	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 158 ALA A 169 LYS A 171 PHE A 222 GLY A 226 ASN A 273 LEU A 275	VIN A6331 (-4.7A) VIN A6331 (-3.4A) None VIN A6331 ( 4.8A) VIN A6331 (-3.4A) VIN A6331 ( 4.8A) VIN A6331 (-4.5A)	0.72A	4wa9B-3dtcA: 27.3	4wa9B-3dtcA: 34.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3iec	SERINE/THREONINE-PRO TEIN KINASE MARK2 (Homo sapiens)	PF00069 (Pkinase) PF00627 (UBA)	7	VAL A 67 ALA A 80 LYS A 82 GLY A 135 ASN A 180 LEU A 182 ALA A 192	None	0.88A	4wa9B-3iecA: 24.5	4wa9B-3iecA: 25.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3kul	EPHRIN TYPE-A RECEPTOR 8 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	VAL A 649 ALA A 665 LYS A 667 THR A 713 MET A 716 GLY A 719 LEU A 767	None None None None None GOL A 403 (-3.4A) None	0.69A	4wa9B-3kulA: 34.8	4wa9B-3kulA: 34.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3kul	EPHRIN TYPE-A RECEPTOR 8 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	VAL A 649 ALA A 665 THR A 713 MET A 716 GLY A 719 ASN A 765 LEU A 767	None None None None GOL A 403 (-3.4A) None None	0.63A	4wa9B-3kulA: 34.8	4wa9B-3kulA: 34.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mdy	BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (Homo sapiens)	PF07714 (Pkinase_Tyr) PF08515 (TGF_beta_GS)	7	VAL A 218 ALA A 229 LYS A 231 THR A 279 GLY A 285 LEU A 339 ALA A 349	LDN A 1 ( 4.8A) LDN A 1 (-3.6A) None LDN A 1 (-3.8A) LDN A 1 (-3.3A) LDN A 1 (-4.5A) LDN A 1 ( 3.8A)	0.83A	4wa9B-3mdyA: 26.7	4wa9B-3mdyA: 28.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3my0	SERINE/THREONINE-PRO TEIN KINASE RECEPTOR R3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 216 ALA A 227 THR A 277 GLY A 283 ASN A 335 LEU A 337 ALA A 347	LDN A 600 (-4.5A) LDN A 600 (-3.2A) LDN A 600 (-4.0A) LDN A 600 (-3.3A) LDN A 600 (-4.5A) LDN A 600 (-4.6A) LDN A 600 ( 3.8A)	0.80A	4wa9B-3my0A: 25.6	4wa9B-3my0A: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3niz	RHODANESE FAMILY PROTEIN (Cryptosporidium parvum)	PF00069 (Pkinase)	7	VAL A 37 ALA A 49 PHE A 100 MET A 101 ASN A 149 LEU A 151 ALA A 161	ADP A 314 (-4.0A) ADP A 314 (-3.5A) ADP A 314 ( 4.3A) None MG A 312 ( 2.9A) ADP A 314 (-4.6A) None	0.66A	4wa9B-3nizA: 24.0	4wa9B-3nizA: 26.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 734 ALA A 751 THR A 798 MET A 801 GLY A 804 ASN A 850 LEU A 852	03Q A 1 (-4.5A) 03Q A 1 (-3.1A) 03Q A 1 (-4.1A) None 03Q A 1 ( 3.9A) 03Q A 1 (-4.2A) 03Q A 1 (-4.4A)	0.76A	4wa9B-3pp0A: 32.4	4wa9B-3pp0A: 35.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q4t	ACTIVIN RECEPTOR TYPE-2A (Homo sapiens)	PF00069 (Pkinase)	7	ALA A 217 THR A 267 PHE A 269 GLY A 273 ASN A 327 LEU A 329 ALA A 339	TAK A 2 (-3.5A) TAK A 2 (-3.5A) TAK A 2 (-4.3A) TAK A 2 (-3.6A) None TAK A 2 (-4.6A) TAK A 2 ( 4.2A)	0.65A	4wa9B-3q4tA: 25.5	4wa9B-3q4tA: 25.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q4t	ACTIVIN RECEPTOR TYPE-2A (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 206 ALA A 217 THR A 267 GLY A 273 ASN A 327 LEU A 329 ALA A 339	TAK A 2 ( 4.9A) TAK A 2 (-3.5A) TAK A 2 (-3.5A) TAK A 2 (-3.6A) None TAK A 2 (-4.6A) TAK A 2 ( 4.2A)	0.70A	4wa9B-3q4tA: 25.5	4wa9B-3q4tA: 25.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q5i	PROTEIN KINASE (Plasmodium berghei)	PF00069 (Pkinase) PF13499 (EF-hand_7)	7	VAL A 71 ALA A 84 LYS A 86 THR A 144 PHE A 146 GLY A 150 LEU A 197	ANP A1634 (-4.1A) ANP A1634 (-3.6A) ANP A1634 (-3.1A) ANP A1634 (-4.6A) ANP A1634 (-4.8A) None ANP A1634 (-4.4A)	0.68A	4wa9B-3q5iA: 22.2	4wa9B-3q5iA: 21.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q5i	PROTEIN KINASE (Plasmodium berghei)	PF00069 (Pkinase) PF13499 (EF-hand_7)	7	VAL A 71 ALA A 84 THR A 144 PHE A 146 GLY A 150 ASN A 195 LEU A 197	ANP A1634 (-4.1A) ANP A1634 (-3.6A) ANP A1634 (-4.6A) ANP A1634 (-4.8A) None CA A 528 ( 3.0A) ANP A1634 (-4.4A)	0.69A	4wa9B-3q5iA: 22.2	4wa9B-3q5iA: 21.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3tt0	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 492 ALA A 512 LYS A 514 GLY A 567 ASN A 628 LEU A 630 ALA A 640	07J A 1 (-4.0A) 07J A 1 (-3.5A) 07J A 1 (-4.5A) 07J A 1 (-3.7A) None 07J A 1 ( 4.4A) 07J A 1 (-3.2A)	0.85A	4wa9B-3tt0A: 31.1	4wa9B-3tt0A: 38.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3txo	PROTEIN KINASE C ETA TYPE (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	VAL A 369 ALA A 382 LYS A 384 PHE A 435 GLY A 439 LEU A 486 ALA A 496	07U A 1 (-4.8A) 07U A 1 (-3.3A) 07U A 1 (-3.0A) None None 07U A 1 (-4.3A) 07U A 1 ( 4.0A)	0.77A	4wa9B-3txoA: 13.8	4wa9B-3txoA: 25.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3txo	PROTEIN KINASE C ETA TYPE (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	VAL A 369 ALA A 382 PHE A 435 GLY A 439 ASN A 484 LEU A 486 ALA A 496	07U A 1 (-4.8A) 07U A 1 (-3.3A) None None None 07U A 1 (-4.3A) 07U A 1 ( 4.0A)	0.78A	4wa9B-3txoA: 13.8	4wa9B-3txoA: 25.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3vid	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 848 ALA A 866 LYS A 868 PHE A 918 GLY A 922 ASN A1033 LEU A1035	4TT A2001 ( 4.5A) 4TT A2001 (-3.5A) None 4TT A2001 (-4.5A) 4TT A2001 (-3.7A) None 4TT A2001 (-4.8A)	0.75A	4wa9B-3vidA: 30.3	4wa9B-3vidA: 34.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3wzd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 848 ALA A 866 LYS A 868 PHE A 918 GLY A 922 ASN A1033 LEU A1035	LEV A1201 ( 4.9A) LEV A1201 (-3.5A) None LEV A1201 (-4.7A) LEV A1201 (-3.6A) GOL A1210 (-3.6A) LEV A1201 (-4.8A)	0.87A	4wa9B-3wzdA: 32.3	4wa9B-3wzdA: 37.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A1959 ALA A1978 LYS A1980 MET A2029 GLY A2032 ASN A2084 LEU A2086	None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) None VGH A3000 (-3.5A) None VGH A3000 (-4.3A)	0.99A	4wa9B-3zbfA: 26.6	4wa9B-3zbfA: 40.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3zfx	EPHRIN TYPE-B RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 633 ALA A 649 THR A 697 PHE A 699 MET A 700 GLY A 703 ASN A 749 LEU A 751	None	0.64A	4wa9B-3zfxA: 33.3	4wa9B-3zfxA: 41.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4aw5	EPHRIN TYPE-B RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 105 ALA A 121 LYS A 123 THR A 169 PHE A 171 MET A 172 ASN A 221	30K A1365 ( 4.6A) 30K A1365 (-3.2A) 30K A1365 (-3.8A) 30K A1365 (-3.8A) 30K A1365 (-4.4A) None 30K A1365 (-4.4A)	0.93A	4wa9B-4aw5A: 32.4	4wa9B-4aw5A: 38.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4aw5	EPHRIN TYPE-B RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 105 ALA A 121 THR A 169 PHE A 171 MET A 172 GLY A 175 ASN A 221 LEU A 223	30K A1365 ( 4.6A) 30K A1365 (-3.2A) 30K A1365 (-3.8A) 30K A1365 (-4.4A) None 30K A1365 (-3.5A) 30K A1365 (-4.4A) 30K A1365 (-4.5A)	0.67A	4wa9B-4aw5A: 32.4	4wa9B-4aw5A: 38.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4bc6	SERINE/THREONINE-PRO TEIN KINASE 10 (Homo sapiens)	PF00069 (Pkinase)	8	VAL A 50 ALA A 63 LYS A 65 PHE A 112 GLY A 116 ASN A 162 LEU A 164 ALA A 174	XZN A1317 ( 4.7A) XZN A1317 (-3.5A) XZN A1317 (-4.1A) XZN A1317 (-4.5A) XZN A1317 ( 3.7A) None XZN A1317 (-4.7A) XZN A1317 ( 4.3A)	1.13A	4wa9B-4bc6A: 22.2	4wa9B-4bc6A: 29.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c02	ACTIVIN RECEPTOR TYPE-1 (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	7	VAL A 222 ALA A 233 THR A 283 GLY A 289 ASN A 341 LEU A 343 ALA A 353	TAK A1507 (-4.7A) TAK A1507 (-3.3A) TAK A1507 (-3.6A) TAK A1507 (-3.5A) None TAK A1507 (-4.7A) TAK A1507 ( 4.2A)	0.74A	4wa9B-4c02A: 26.0	4wa9B-4c02A: 27.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ckr	EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	VAL A 624 ALA A 653 LYS A 655 THR A 701 MET A 704 GLY A 707 ASN A 771 LEU A 773 ALA A 783	DI1 A1000 (-4.8A) DI1 A1000 (-3.6A) DI1 A1000 (-3.9A) DI1 A1000 (-3.6A) None None None DI1 A1000 (-4.5A) DI1 A1000 (-3.7A)	0.71A	4wa9B-4ckrA: 29.8	4wa9B-4ckrA: 37.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f0i	HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 523 ALA A 541 LYS A 543 MET A 591 GLY A 594 ASN A 654 LEU A 656	None	0.70A	4wa9B-4f0iA: 24.6	4wa9B-4f0iA: 36.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	VAL A 281 ALA A 293 MET A 341 GLY A 344 ASN A 391 LEU A 393 ALA A 403	0J9 A 601 (-4.4A) 0J9 A 601 (-3.3A) None 0J9 A 601 ( 4.1A) None 0J9 A 601 (-4.5A) 0J9 A 601 (-3.5A)	0.79A	4wa9B-4k11A: 30.5	4wa9B-4k11A: 35.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lgg	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus)	PF07714 (Pkinase_Tyr)	7	VAL A 281 ALA A 293 MET A 341 GLY A 344 ASN A 391 LEU A 393 ALA A 403	VGG A 601 ( 3.5A) VGG A 601 (-3.5A) None VGG A 601 ( 3.2A) None VGG A 601 (-4.5A) VGG A 601 ( 4.2A)	0.77A	4wa9B-4lggA: 29.9	4wa9B-4lggA: 46.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4m69	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 3 (Mus musculus)	PF00069 (Pkinase)	7	ALA A 49 THR A 95 PHE A 97 MET A 98 GLY A 101 LEU A 150 ALA A 160	ANP A 401 (-3.1A) ANP A 401 (-3.8A) ANP A 401 (-3.8A) None None ANP A 401 (-4.8A) None	0.85A	4wa9B-4m69A: 24.4	4wa9B-4m69A: 29.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4m69	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 3 (Mus musculus)	PF00069 (Pkinase)	7	VAL A 36 ALA A 49 THR A 95 MET A 98 GLY A 101 LEU A 150 ALA A 160	ANP A 401 (-4.5A) ANP A 401 (-3.1A) ANP A 401 (-3.8A) None None ANP A 401 (-4.8A) None	0.78A	4wa9B-4m69A: 24.4	4wa9B-4m69A: 29.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 54 ALA A 67 LYS A 69 THR A 123 GLY A 128 ASN A 178 LEU A 180	None SIN A 401 ( 3.7A) None None SIN A 401 (-3.5A) None SIN A 401 ( 4.5A)	0.71A	4wa9B-4o38A: 20.7	4wa9B-4o38A: 25.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4p2k	EPHRIN TYPE-A RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	VAL A 627 ALA A 644 THR A 692 MET A 695 GLY A 698 ASN A 744 LEU A 746	None	0.85A	4wa9B-4p2kA: 32.6	4wa9B-4p2kA: 38.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	7	VAL A 22 ALA A 35 LYS A 37 THR A 81 MET A 84 LEU A 136 ALA A 146	ACP A1264 (-4.7A) ACP A1264 (-2.9A) None ACP A1264 (-4.5A) None ACP A1264 ( 4.8A) None	0.82A	4wa9B-4ueuA: 33.7	4wa9B-4ueuA: 64.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	8	VAL A 22 ALA A 35 THR A 81 MET A 84 GLY A 87 ASN A 134 LEU A 136 ALA A 146	ACP A1264 (-4.7A) ACP A1264 (-2.9A) ACP A1264 (-4.5A) None ACP A1264 (-3.5A) None ACP A1264 ( 4.8A) None	0.65A	4wa9B-4ueuA: 33.7	4wa9B-4ueuA: 64.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	7	ALA A 61 PHE A 110 GLY A 114 ASN A 160 LEU A 162 ALA A 172 PHE A 174	6UI A 700 (-3.3A) 6UI A 700 (-4.3A) 6UI A 700 ( 4.2A) None 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A) None	1.31A	4wa9B-4usfA: 18.0	4wa9B-4usfA: 29.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 48 ALA A 61 PHE A 110 GLY A 114 ASN A 160 LEU A 162 ALA A 172	None 6UI A 700 (-3.3A) 6UI A 700 (-4.3A) 6UI A 700 ( 4.2A) None 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A)	1.04A	4wa9B-4usfA: 18.0	4wa9B-4usfA: 29.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wsq	AP2-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 60 ALA A 72 LYS A 74 PHE A 128 GLY A 132 ASN A 181 LEU A 183	KSA A 405 ( 4.9A) KSA A 405 (-3.2A) None KSA A 405 (-4.8A) KSA A 405 (-3.5A) KSA A 405 (-4.0A) KSA A 405 (-4.6A)	0.78A	4wa9B-4wsqA: 24.0	4wa9B-4wsqA: 24.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xcu	FIBROBLAST GROWTH FACTOR RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 481 ALA A 501 LYS A 503 GLY A 556 ASN A 617 LEU A 619 ALA A 629	40M A1002 ( 4.5A) 40M A1002 ( 4.1A) 40M A1002 (-4.0A) 40M A1002 ( 3.7A) None 40M A1002 (-4.5A) 40M A1002 (-3.0A)	0.93A	4wa9B-4xcuA: 31.5	4wa9B-4xcuA: 40.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	9	VAL B 275 ALA B 288 THR B 334 PHE B 336 MET B 337 GLY B 340 ASN B 387 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) None 1N1 B 601 (-3.5A) None 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.48A	4wa9B-4xeyB: 40.8	4wa9B-4xeyB: 78.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	9	VAL B 275 ALA B 288 THR B 334 PHE B 336 MET B 337 GLY B 340 LEU B 389 ALA B 399 PHE B 401	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A) None	1.09A	4wa9B-4xeyB: 40.8	4wa9B-4xeyB: 78.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	7	VAL A 416 ALA A 428 THR A 474 MET A 477 GLY A 480 ASN A 526 LEU A 528	746 A 702 ( 4.3A) 746 A 702 (-2.4A) 746 A 702 (-3.7A) None 746 A 702 (-3.6A) 746 A 702 (-2.8A) 746 A 702 (-4.4A)	0.56A	4wa9B-4y93A: 30.8	4wa9B-4y93A: 29.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yff	SERINE/THREONINE-PRO TEIN KINASE TNNI3K (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 477 ALA A 488 LYS A 490 THR A 539 GLY A 545 LEU A 595 ALA A 605	None 4CV A 801 (-3.5A) 4CV A 801 (-3.9A) 4CV A 801 (-2.8A) 4CV A 801 ( 4.0A) 4CV A 801 (-4.4A) 4CV A 801 ( 3.9A)	0.72A	4wa9B-4yffA: 26.3	4wa9B-4yffA: 28.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5e8y	TGF-BETA RECEPTOR TYPE-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 258 ALA A 275 LYS A 277 THR A 325 PHE A 327 GLY A 331 LEU A 386	STU A 601 (-4.0A) STU A 601 (-3.1A) STU A 601 (-2.4A) STU A 601 ( 3.7A) STU A 601 (-3.4A) STU A 601 (-3.5A) STU A 601 (-3.9A)	0.86A	4wa9B-5e8yA: 19.8	4wa9B-5e8yA: 27.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5e8y	TGF-BETA RECEPTOR TYPE-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 258 ALA A 275 THR A 325 PHE A 327 GLY A 331 ASN A 384 LEU A 386	STU A 601 (-4.0A) STU A 601 (-3.1A) STU A 601 ( 3.7A) STU A 601 (-3.4A) STU A 601 (-3.5A) STU A 601 ( 4.9A) STU A 601 (-3.9A)	0.63A	4wa9B-5e8yA: 19.8	4wa9B-5e8yA: 27.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5iso	5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-2 (Homo sapiens)	PF00069 (Pkinase) PF16579 (AdenylateSensor)	7	VAL A 30 ALA A 43 LYS A 45 GLY A 99 ASN A 144 LEU A 146 ALA A 156	STU A 601 (-4.8A) STU A 601 (-3.3A) STU A 601 ( 4.4A) STU A 601 ( 4.0A) STU A 601 (-4.3A) STU A 601 (-4.5A) STU A 601 (-3.5A)	0.77A	4wa9B-5isoA: 25.1	4wa9B-5isoA: 19.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 30 ALA A 43 LYS A 45 PHE A 92 GLY A 96 LEU A 143 ALA A 153	6G2 A 901 ( 4.9A) 6G2 A 901 (-3.2A) 6G2 A 901 ( 3.9A) 6G2 A 901 (-4.1A) 6G2 A 901 (-3.6A) 6G2 A 901 (-4.7A) 6G2 A 901 ( 4.2A)	0.69A	4wa9B-5j5tA: 22.1	4wa9B-5j5tA: 24.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 30 ALA A 43 PHE A 92 GLY A 96 ASN A 141 LEU A 143 ALA A 153	6G2 A 901 ( 4.9A) 6G2 A 901 (-3.2A) 6G2 A 901 (-4.1A) 6G2 A 901 (-3.6A) None 6G2 A 901 (-4.7A) 6G2 A 901 ( 4.2A)	0.62A	4wa9B-5j5tA: 22.1	4wa9B-5j5tA: 24.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5l6o	EPHRIN TYPE-B RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A 663 THR A 711 PHE A 713 MET A 714 ASN A 763 LEU A 765 PHE A 777	6P6 A1001 (-3.3A) 6P6 A1001 (-3.5A) 6P6 A1001 ( 4.5A) None None 6P6 A1001 (-4.5A) DIO A1002 (-4.5A)	1.30A	4wa9B-5l6oA: 31.4	4wa9B-5l6oA: 38.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5l6o	EPHRIN TYPE-B RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 647 ALA A 663 LYS A 665 PHE A 713 MET A 714 ASN A 763 LEU A 765	None 6P6 A1001 (-3.3A) None 6P6 A1001 ( 4.5A) None None 6P6 A1001 (-4.5A)	0.78A	4wa9B-5l6oA: 31.4	4wa9B-5l6oA: 38.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5l6o	EPHRIN TYPE-B RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 647 ALA A 663 THR A 711 PHE A 713 MET A 714 ASN A 763 LEU A 765	None 6P6 A1001 (-3.3A) 6P6 A1001 (-3.5A) 6P6 A1001 ( 4.5A) None None 6P6 A1001 (-4.5A)	0.62A	4wa9B-5l6oA: 31.4	4wa9B-5l6oA: 38.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpy	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	7	VAL A 897 ALA A 909 LYS A 911 PHE A 958 MET A 959 GLY A 962 LEU A1016	ATP A1200 ( 4.5A) ATP A1200 (-3.5A) ATP A1200 (-3.8A) ATP A1200 ( 4.0A) None ATP A1200 ( 4.0A) ATP A1200 (-4.6A)	0.63A	4wa9B-5lpyA: 24.7	4wa9B-5lpyA: 28.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpy	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	7	VAL A 897 ALA A 909 PHE A 958 MET A 959 GLY A 962 ASN A1014 LEU A1016	ATP A1200 ( 4.5A) ATP A1200 (-3.5A) ATP A1200 ( 4.0A) None ATP A1200 ( 4.0A) ATP A1200 (-3.6A) ATP A1200 (-4.6A)	0.53A	4wa9B-5lpyA: 24.7	4wa9B-5lpyA: 28.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpz	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	7	VAL A 897 ALA A 909 PHE A 958 MET A 959 GLY A 962 ASN A1014 LEU A1016	ADP A1200 (-4.4A) ADP A1200 (-3.5A) ADP A1200 (-4.1A) None ADP A1200 ( 4.0A) ADP A1200 (-3.6A) ADP A1200 (-4.7A)	0.46A	4wa9B-5lpzA: 24.8	4wa9B-5lpzA: 29.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 601 ALA A 617 PHE A 673 MET A 674 GLY A 677 ASN A 728 ALA A 740	7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) 7AE A1000 (-4.1A) None 7AE A1000 ( 3.7A) 7AE A1000 (-4.7A) 7AE A1000 ( 3.7A)	0.61A	4wa9B-5td2A: 29.0	4wa9B-5td2A: 42.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5tos	SERINE/THREONINE-PRO TEIN KINASE BIK1 (Arabidopsis thaliana)	no annotation	7	VAL A 81 ALA A 103 LYS A 105 MET A 153 GLY A 156 ASN A 207 LEU A 209	None	1.09A	4wa9B-5tosA: 18.2	4wa9B-5tosA: 12.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5tos	SERINE/THREONINE-PRO TEIN KINASE BIK1 (Arabidopsis thaliana)	no annotation	7	VAL A 81 ALA A 103 PHE A 152 MET A 153 GLY A 156 ASN A 207 LEU A 209	None	0.78A	4wa9B-5tosA: 18.2	4wa9B-5tosA: 12.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 550 ALA A 565 LYS A 567 PHE A 622 MET A 623 GLY A 626 ALA A 689	7YS A9001 (-4.2A) 7YS A9001 (-3.3A) None 7YS A9001 (-4.3A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A) 7YS A9001 (-3.4A)	0.77A	4wa9B-5u6bA: 30.2	4wa9B-5u6bA: 43.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 550 ALA A 565 PHE A 622 MET A 623 GLY A 626 ASN A 677 ALA A 689	7YS A9001 (-4.2A) 7YS A9001 (-3.3A) 7YS A9001 (-4.3A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A) None 7YS A9001 (-3.4A)	0.78A	4wa9B-5u6bA: 30.2	4wa9B-5u6bA: 43.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5w5j	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2 (Homo sapiens)	no annotation	8	VAL A 32 ALA A 45 THR A 95 MET A 98 GLY A 101 ASN A 151 LEU A 153 ALA A 163	9WS A 401 ( 4.6A) 9WS A 401 (-3.3A) 9WS A 401 (-3.2A) None 9WS A 401 ( 4.3A) None 9WS A 401 (-4.6A) 9WS A 401 ( 4.0A)	0.64A	4wa9B-5w5jA: 24.2	4wa9B-5w5jA: 27.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xzw	SERINE/THREONINE-PRO TEIN KINASE RAD53 (Saccharomyces cerevisiae)	no annotation	7	VAL A 212 ALA A 225 LYS A 227 PHE A 275 GLY A 279 ASN A 324 LEU A 326	None	0.88A	4wa9B-5xzwA: 19.3	4wa9B-5xzwA: 22.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cmj	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 2 (Homo sapiens)	no annotation	7	VAL A 179 ALA A 192 LYS A 194 GLY A 273 ASN A 317 LEU A 319 ALA A 329	F6J A 501 (-4.6A) F6J A 501 (-3.4A) F6J A 501 (-2.9A) F6J A 501 ( 3.7A) F6J A 501 ( 4.7A) F6J A 501 (-4.5A) F6J A 501 ( 4.0A)	0.73A	4wa9B-6cmjA: 24.4	4wa9B-6cmjA: 14.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cz4	PROTEIN-TYROSINE KINASE 6 (Homo sapiens)	no annotation	7	VAL A 205 ALA A 217 THR A 264 MET A 267 GLY A 270 ASN A 317 LEU A 319	FKY A9001 ( 4.6A) FKY A9001 (-3.3A) FKY A9001 (-3.0A) None FKY A9001 (-3.3A) None FKY A9001 ( 4.9A)	0.94A	4wa9B-6cz4A: 29.3	4wa9B-6cz4A: 18.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fdy	- (-)	no annotation	7	VAL U 28 ALA U 42 LYS U 44 PHE U 93 GLY U 97 LEU U 144 ALA U 156	DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.0A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.98A	4wa9B-6fdyU: 23.8	4wa9B-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fdy	- (-)	no annotation	7	VAL U 28 ALA U 42 PHE U 93 GLY U 97 ASN U 142 LEU U 144 ALA U 156	DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.4A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.5A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.82A	4wa9B-6fdyU: 23.8	4wa9B-6fdyU: undetectable

[["4WA9_B_AXIB9000_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",7,"VAL A 416;ALA A 428;LYS A 430;THR A 474;MET A 477;GLY A 480;LEU A 528","None","0.79A","4wa9B-1k2pA:31.4","4wa9B-1k2pA:45.26"],["4WA9_B_AXIB9000_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",7,"VAL A 416;ALA A 428;THR A 474;MET A 477;GLY A 480;ASN A 526;LEU A 528","None","0.81A","4wa9B-1k2pA:31.4","4wa9B-1k2pA:45.26"],["4WA9_B_AXIB9000_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"VAL A 209;ALA A 220;LYS A 222;THR A 266;MET A 269;GLY A 272;LEU A 321","None","0.72A","4wa9B-1k9aA:32.2","4wa9B-1k9aA:29.70"],["4WA9_B_AXIB9000_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"VAL A 209;ALA A 220;THR A 266;MET A 269;GLY A 272;ASN A 319;LEU A 321","None","0.60A","4wa9B-1k9aA:32.2","4wa9B-1k9aA:29.70"],["4WA9_B_AXIB9000_1","1luf","Rattus norvegicus","MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK","PF07714(Pkinase_Tyr)",8,"VAL A 588;ALA A 606;LYS A 608;MET A 657;GLY A 660;ASN A 729;LEU A 731;ALA A 741","None","0.58A","4wa9B-1lufA:32.4","4wa9B-1lufA:36.68"],["4WA9_B_AXIB9000_1","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"TYR A 272;VAL A 275;ALA A 288;THR A 334;MET A 337;GLY A 340;LEU A 389;ALA A 399","P16 A   2 (-3.6A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-3.7A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.79A","4wa9B-1opkA:37.8","4wa9B-1opkA:57.72"],["4WA9_B_AXIB9000_1","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",10,"VAL A 275;ALA A 288;LYS A 290;THR A 334;PHE A 336;MET A 337;GLY A 340;ASN A 387;LEU A 389;ALA A 399","P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);None;P16 A   2 (-3.4A);None;P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.54A","4wa9B-1opkA:37.8","4wa9B-1opkA:57.72"],["4WA9_B_AXIB9000_1","2ac5","Homo sapiens","MAP KINASE-INTERACTING SERINE\/THREONINE KINASE 2","PF00069(Pkinase)",7,"VAL A  98;ALA A 111;LYS A 113;MET A 162;GLY A 165;ASN A 210;LEU A 212","None","0.75A","4wa9B-2ac5A:20.4","4wa9B-2ac5A:24.13"],["4WA9_B_AXIB9000_1","2buj","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 16","PF00069(Pkinase)",7,"VAL A  34;ALA A  47;LYS A  49;PHE A 100;GLY A 104;ASN A 153;LEU A 155","STU A1301 (-4.8A);STU A1301 (-3.6A);STU A1301 ( 4.0A);STU A1301 (-4.5A);STU A1301 ( 4.0A);None;STU A1301 ( 4.8A)","0.71A","4wa9B-2bujA:24.2","4wa9B-2bujA:23.33"],["4WA9_B_AXIB9000_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",8,"VAL X  25;ALA X  37;LYS X  39;THR X  82;MET X  85;GLY X  88;LEU X 137;ALA X 147","STU X 902 ( 4.8A);STU X 902 (-3.1A);STU X 902 (-3.1A);STU X 902 (-4.1A);None;STU X 902 (-3.5A);STU X 902 (-4.4A);STU X 902 ( 4.1A)","0.71A","4wa9B-2dq7X:35.4","4wa9B-2dq7X:45.30"],["4WA9_B_AXIB9000_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",8,"VAL X  25;ALA X  37;THR X  82;MET X  85;GLY X  88;ASN X 135;LEU X 137;ALA X 147","STU X 902 ( 4.8A);STU X 902 (-3.1A);STU X 902 (-4.1A);None;STU X 902 (-3.5A);STU X 902 ( 4.9A);STU X 902 (-4.4A);STU X 902 ( 4.1A)","0.50A","4wa9B-2dq7X:35.4","4wa9B-2dq7X:45.30"],["4WA9_B_AXIB9000_1","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"VAL A 281;ALA A 293;THR A 338;MET A 341;GLY A 344;ASN A 391;LEU A 393;ALA A 403","H8H A 534 (-4.4A);H8H A 534 (-3.2A);H8H A 534 (-3.1A);None;H8H A 534 (-3.3A);H8H A 534 ( 4.9A);H8H A 534 (-4.5A);H8H A 534 ( 4.0A)","0.80A","4wa9B-2h8hA:30.4","4wa9B-2h8hA:27.78"],["4WA9_B_AXIB9000_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"ALA A 293;THR A 338;PHE A 340;MET A 341;GLY A 344;ASN A 391;LEU A 393;ALA A 403","QUE A   1 (-3.5A);QUE A   1 (-3.3A);QUE A   1 (-4.2A);None;QUE A   1 (-3.0A);None;QUE A   1 (-4.4A);QUE A   1 ( 4.5A)","0.58A","4wa9B-2hckA:30.4","4wa9B-2hckA:33.42"],["4WA9_B_AXIB9000_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"VAL A 281;ALA A 293;LYS A 295;THR A 338;PHE A 340;MET A 341;LEU A 393;ALA A 403","QUE A   1 ( 4.8A);QUE A   1 (-3.5A);None;QUE A   1 (-3.3A);QUE A   1 (-4.2A);None;QUE A   1 (-4.4A);QUE A   1 ( 4.5A)","1.17A","4wa9B-2hckA:30.4","4wa9B-2hckA:33.42"],["4WA9_B_AXIB9000_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"VAL A 281;ALA A 293;THR A 338;PHE A 340;MET A 341;ASN A 391;LEU A 393;ALA A 403","QUE A   1 ( 4.8A);QUE A   1 (-3.5A);QUE A   1 (-3.3A);QUE A   1 (-4.2A);None;None;QUE A   1 (-4.4A);QUE A   1 ( 4.5A)","0.85A","4wa9B-2hckA:30.4","4wa9B-2hckA:33.42"],["4WA9_B_AXIB9000_1","2hen","Mus musculus","EPHRIN TYPE-B RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"VAL A 643;ALA A 659;THR A 707;MET A 710;GLY A 713;ASN A 759;LEU A 761","ADP A 400 ( 4.4A);ADP A 400 (-3.2A);ADP A 400 (-4.7A);None;ADP A 400 ( 4.2A); MG A 404 (-4.5A);ADP A 400 ( 4.7A)","0.92A","4wa9B-2henA:31.4","4wa9B-2henA:39.73"],["4WA9_B_AXIB9000_1","2hen","Mus musculus","EPHRIN TYPE-B RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"VAL A 643;ALA A 659;THR A 707;PHE A 709;MET A 710;GLY A 713;LEU A 761","ADP A 400 ( 4.4A);ADP A 400 (-3.2A);ADP A 400 (-4.7A);None;None;ADP A 400 ( 4.2A);ADP A 400 ( 4.7A)","0.72A","4wa9B-2henA:31.4","4wa9B-2henA:39.73"],["4WA9_B_AXIB9000_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",9,"VAL A 259;ALA A 271;LYS A 273;THR A 316;PHE A 318;MET A 319;GLY A 322;LEU A 371;ALA A 381","1BM A 499 ( 4.8A);1BM A 499 (-3.6A);1BM A 499 (-3.8A);1BM A 499 (-3.2A);1BM A 499 (-4.1A);None;1BM A 499 (-3.5A);1BM A 499 (-4.4A);1BM A 499 ( 3.7A)","0.79A","4wa9B-2hk5A:35.2","4wa9B-2hk5A:46.81"],["4WA9_B_AXIB9000_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",9,"VAL A 259;ALA A 271;THR A 316;PHE A 318;MET A 319;GLY A 322;ASN A 369;LEU A 371;ALA A 381","1BM A 499 ( 4.8A);1BM A 499 (-3.6A);1BM A 499 (-3.2A);1BM A 499 (-4.1A);None;1BM A 499 (-3.5A);1BM A 499 (-4.1A);1BM A 499 (-4.4A);1BM A 499 ( 3.7A)","0.69A","4wa9B-2hk5A:35.2","4wa9B-2hk5A:46.81"],["4WA9_B_AXIB9000_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",9,"VAL A 256;ALA A 269;LYS A 271;THR A 315;PHE A 317;MET A 318;GLY A 321;LEU A 370;ALA A 380","GIN A 600 ( 4.7A);GIN A 600 (-3.1A);GIN A 600 (-3.6A);GIN A 600 (-3.4A);GIN A 600 (-4.3A);None;None;GIN A 600 (-4.7A);GIN A 600 (-3.1A)","0.63A","4wa9B-2hz0A:34.9","4wa9B-2hz0A:99.26"],["4WA9_B_AXIB9000_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",9,"VAL A 256;ALA A 269;THR A 315;PHE A 317;MET A 318;GLY A 321;ASN A 368;LEU A 370;ALA A 380","GIN A 600 ( 4.7A);GIN A 600 (-3.1A);GIN A 600 (-3.4A);GIN A 600 (-4.3A);None;None;None;GIN A 600 (-4.7A);GIN A 600 (-3.1A)","0.64A","4wa9B-2hz0A:34.9","4wa9B-2hz0A:99.26"],["4WA9_B_AXIB9000_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",8,"VAL A 259;ALA A 271;LYS A 273;THR A 316;MET A 319;GLY A 322;LEU A 371;ALA A 381","None;1N8 A 501 ( 3.4A);1N8 A 501 ( 3.4A);1N8 A 501 ( 3.3A);1N8 A 501 ( 4.4A);1N8 A 501 ( 3.5A);1N8 A 501 ( 4.3A);1N8 A 501 ( 3.3A)","0.78A","4wa9B-2og8A:31.4","4wa9B-2og8A:45.77"],["4WA9_B_AXIB9000_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",8,"VAL A 259;ALA A 271;THR A 316;MET A 319;GLY A 322;ASN A 369;LEU A 371;ALA A 381","None;1N8 A 501 ( 3.4A);1N8 A 501 ( 3.3A);1N8 A 501 ( 4.4A);1N8 A 501 ( 3.5A);None;1N8 A 501 ( 4.3A);1N8 A 501 ( 3.3A)","0.70A","4wa9B-2og8A:31.4","4wa9B-2og8A:45.77"],["4WA9_B_AXIB9000_1","2qlu","Homo sapiens","ACTIVIN RECEPTOR TYPE IIB","PF00069(Pkinase)",7,"VAL A 204;ALA A 215;LYS A 217;THR A 265;PHE A 267;LEU A 328;ALA A 338","ADE A 488 ( 4.9A);ADE A 488 (-3.2A);None;ADE A 488 (-4.3A);ADE A 488 (-4.3A);ADE A 488 (-4.4A);None","0.96A","4wa9B-2qluA:26.2","4wa9B-2qluA:25.44"],["4WA9_B_AXIB9000_1","2qlu","Homo sapiens","ACTIVIN RECEPTOR TYPE IIB","PF00069(Pkinase)",8,"VAL A 204;ALA A 215;THR A 265;PHE A 267;GLY A 271;ASN A 326;LEU A 328;ALA A 338","ADE A 488 ( 4.9A);ADE A 488 (-3.2A);ADE A 488 (-4.3A);ADE A 488 (-4.3A);ADE A 488 ( 4.1A);None;ADE A 488 (-4.4A);None","0.74A","4wa9B-2qluA:26.2","4wa9B-2qluA:25.44"],["4WA9_B_AXIB9000_1","2qob","Homo sapiens","EPHRIN RECEPTOR","PF07714(Pkinase_Tyr)",7,"VAL A 635;ALA A 651;THR A 699;MET A 702;GLY A 705;ASN A 751;LEU A 753","BME A   1 (-4.9A);PTR A 701 ( 4.7A);None;PTR A 701 ( 3.5A);None;None;None","0.77A","4wa9B-2qobA:32.1","4wa9B-2qobA:34.49"],["4WA9_B_AXIB9000_1","2r2p","Homo sapiens","EPHRIN TYPE-A RECEPTOR 5","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"VAL A 689;ALA A 705;THR A 753;MET A 756;GLY A 759;ASN A 805;LEU A 807","None","0.58A","4wa9B-2r2pA:34.8","4wa9B-2r2pA:37.54"],["4WA9_B_AXIB9000_1","2xik","Homo sapiens","SERINE\/THREONINE PROTEIN KINASE 25","PF00069(Pkinase)",7,"VAL A  34;ALA A  47;LYS A  49;GLY A 101;ASN A 145;LEU A 147;ALA A 157","J60 A1294 ( 4.9A);J60 A1294 (-3.3A);None;J60 A1294 ( 3.8A);None;J60 A1294 (-4.8A);J60 A1294 ( 4.2A)","0.98A","4wa9B-2xikA:20.5","4wa9B-2xikA:27.30"],["4WA9_B_AXIB9000_1","2xyu","Mus musculus","EPHRIN TYPE-A RECEPTOR 4,","PF07714(Pkinase_Tyr)",8,"VAL A 635;ALA A 651;LYS A 653;THR A 699;MET A 702;GLY A 705;ASN A 751;LEU A 753","Q9G A1898 ( 4.7A);Q9G A1898 (-3.2A);Q9G A1898 (-4.8A);Q9G A1898 (-3.5A);None;Q9G A1898 ( 3.8A);None;Q9G A1898 (-4.3A)","0.77A","4wa9B-2xyuA:32.4","4wa9B-2xyuA:38.57"],["4WA9_B_AXIB9000_1","2y7j","Homo sapiens","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","PF00069(Pkinase)",7,"VAL A  38;ALA A  51;LYS A  53;MET A 110;GLY A 113;ASN A 158;LEU A 160","None;B49 A1294 (-3.2A);None;None;B49 A1294 (-3.6A);None;B49 A1294 (-4.4A)","0.90A","4wa9B-2y7jA:25.4","4wa9B-2y7jA:26.39"],["4WA9_B_AXIB9000_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",7,"VAL A 261;ALA A 273;LYS A 275;THR A 319;PHE A 321;MET A 322;ALA A 384","None","0.84A","4wa9B-2zv7A:32.6","4wa9B-2zv7A:45.45"],["4WA9_B_AXIB9000_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",9,"VAL A 261;ALA A 273;THR A 319;PHE A 321;MET A 322;GLY A 325;ASN A 372;LEU A 374;ALA A 384","None","0.81A","4wa9B-2zv7A:32.6","4wa9B-2zv7A:45.45"],["4WA9_B_AXIB9000_1","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"VAL A 495;ALA A 515;LYS A 517;GLY A 570;ASN A 631;LEU A 633;ALA A 643","M33 A1996 ( 4.7A);M33 A1996 (-3.3A);M33 A1996 ( 4.5A);M33 A1996 ( 4.8A);None;M33 A1996 (-4.5A);None","0.86A","4wa9B-3b2tA:33.4","4wa9B-3b2tA:40.65"],["4WA9_B_AXIB9000_1","3c0i","Homo sapiens","PERIPHERAL PLASMA MEMBRANE PROTEIN CASK","PF00069(Pkinase)",7,"VAL A  26;ALA A  39;LYS A  41;PHE A  93;MET A  94;GLY A  96;LEU A 148","3AM A 338 ( 4.1A);3AM A 338 (-3.3A);3AM A 338 (-2.9A);3AM A 338 ( 4.6A);None;None;3AM A 338 (-4.7A)","0.89A","4wa9B-3c0iA:25.5","4wa9B-3c0iA:25.48"],["4WA9_B_AXIB9000_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",7,"VAL A 209;ALA A 220;LYS A 222;THR A 266;MET A 269;GLY A 272;LEU A 321","None","0.72A","4wa9B-3d7uA:27.5","4wa9B-3d7uA:44.22"],["4WA9_B_AXIB9000_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",7,"VAL A 209;ALA A 220;THR A 266;MET A 269;GLY A 272;ASN A 319;LEU A 321","None","0.60A","4wa9B-3d7uA:27.5","4wa9B-3d7uA:44.22"],["4WA9_B_AXIB9000_1","3dko","Homo sapiens","EPHRIN TYPE-A RECEPTOR 7","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",8,"VAL A 647;ALA A 663;LYS A 665;PHE A 713;MET A 714;GLY A 717;ASN A 763;LEU A 765","IHZ A1001 ( 4.4A);IHZ A1001 (-3.3A);IHZ A1001 ( 4.5A);None;None;IHZ A1001 ( 3.9A);None;IHZ A1001 (-4.6A)","0.92A","4wa9B-3dkoA:30.7","4wa9B-3dkoA:36.48"],["4WA9_B_AXIB9000_1","3dtc","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 9","PF07714(Pkinase_Tyr)",7,"VAL A 158;ALA A 169;LYS A 171;PHE A 222;GLY A 226;ASN A 273;LEU A 275","VIN A6331 (-4.7A);VIN A6331 (-3.4A);None;VIN A6331 ( 4.8A);VIN A6331 (-3.4A);VIN A6331 ( 4.8A);VIN A6331 (-4.5A)","0.72A","4wa9B-3dtcA:27.3","4wa9B-3dtcA:34.80"],["4WA9_B_AXIB9000_1","3iec","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE MARK2","PF00069(Pkinase);PF00627(UBA)",7,"VAL A  67;ALA A  80;LYS A  82;GLY A 135;ASN A 180;LEU A 182;ALA A 192","None","0.88A","4wa9B-3iecA:24.5","4wa9B-3iecA:25.44"],["4WA9_B_AXIB9000_1","3kul","Homo sapiens","EPHRIN TYPE-A RECEPTOR 8","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"VAL A 649;ALA A 665;LYS A 667;THR A 713;MET A 716;GLY A 719;LEU A 767","None;None;None;None;None;GOL A 403 (-3.4A);None","0.69A","4wa9B-3kulA:34.8","4wa9B-3kulA:34.25"],["4WA9_B_AXIB9000_1","3kul","Homo sapiens","EPHRIN TYPE-A RECEPTOR 8","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"VAL A 649;ALA A 665;THR A 713;MET A 716;GLY A 719;ASN A 765;LEU A 767","None;None;None;None;GOL A 403 (-3.4A);None;None","0.63A","4wa9B-3kulA:34.8","4wa9B-3kulA:34.25"],["4WA9_B_AXIB9000_1","3mdy","Homo sapiens","BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B","PF07714(Pkinase_Tyr);PF08515(TGF_beta_GS)",7,"VAL A 218;ALA A 229;LYS A 231;THR A 279;GLY A 285;LEU A 339;ALA A 349","LDN A   1 ( 4.8A);LDN A   1 (-3.6A);None;LDN A   1 (-3.8A);LDN A   1 (-3.3A);LDN A   1 (-4.5A);LDN A   1 ( 3.8A)","0.83A","4wa9B-3mdyA:26.7","4wa9B-3mdyA:28.36"],["4WA9_B_AXIB9000_1","3my0","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE RECEPTOR R3","PF07714(Pkinase_Tyr)",7,"VAL A 216;ALA A 227;THR A 277;GLY A 283;ASN A 335;LEU A 337;ALA A 347","LDN A 600 (-4.5A);LDN A 600 (-3.2A);LDN A 600 (-4.0A);LDN A 600 (-3.3A);LDN A 600 (-4.5A);LDN A 600 (-4.6A);LDN A 600 ( 3.8A)","0.80A","4wa9B-3my0A:25.6","4wa9B-3my0A:28.53"],["4WA9_B_AXIB9000_1","3niz","Cryptosporidium parvum","RHODANESE FAMILY PROTEIN","PF00069(Pkinase)",7,"VAL A  37;ALA A  49;PHE A 100;MET A 101;ASN A 149;LEU A 151;ALA A 161","ADP A 314 (-4.0A);ADP A 314 (-3.5A);ADP A 314 ( 4.3A);None; MG A 312 ( 2.9A);ADP A 314 (-4.6A);None","0.66A","4wa9B-3nizA:24.0","4wa9B-3nizA:26.88"],["4WA9_B_AXIB9000_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",7,"VAL A 734;ALA A 751;THR A 798;MET A 801;GLY A 804;ASN A 850;LEU A 852","03Q A   1 (-4.5A);03Q A   1 (-3.1A);03Q A   1 (-4.1A);None;03Q A   1 ( 3.9A);03Q A   1 (-4.2A);03Q A   1 (-4.4A)","0.76A","4wa9B-3pp0A:32.4","4wa9B-3pp0A:35.95"],["4WA9_B_AXIB9000_1","3q4t","Homo sapiens","ACTIVIN RECEPTOR TYPE-2A","PF00069(Pkinase)",7,"ALA A 217;THR A 267;PHE A 269;GLY A 273;ASN A 327;LEU A 329;ALA A 339","TAK A   2 (-3.5A);TAK A   2 (-3.5A);TAK A   2 (-4.3A);TAK A   2 (-3.6A);None;TAK A   2 (-4.6A);TAK A   2 ( 4.2A)","0.65A","4wa9B-3q4tA:25.5","4wa9B-3q4tA:25.07"],["4WA9_B_AXIB9000_1","3q4t","Homo sapiens","ACTIVIN RECEPTOR TYPE-2A","PF00069(Pkinase)",7,"VAL A 206;ALA A 217;THR A 267;GLY A 273;ASN A 327;LEU A 329;ALA A 339","TAK A   2 ( 4.9A);TAK A   2 (-3.5A);TAK A   2 (-3.5A);TAK A   2 (-3.6A);None;TAK A   2 (-4.6A);TAK A   2 ( 4.2A)","0.70A","4wa9B-3q4tA:25.5","4wa9B-3q4tA:25.07"],["4WA9_B_AXIB9000_1","3q5i","Plasmodium berghei","PROTEIN KINASE","PF00069(Pkinase);PF13499(EF-hand_7)",7,"VAL A  71;ALA A  84;LYS A  86;THR A 144;PHE A 146;GLY A 150;LEU A 197","ANP A1634 (-4.1A);ANP A1634 (-3.6A);ANP A1634 (-3.1A);ANP A1634 (-4.6A);ANP A1634 (-4.8A);None;ANP A1634 (-4.4A)","0.68A","4wa9B-3q5iA:22.2","4wa9B-3q5iA:21.43"],["4WA9_B_AXIB9000_1","3q5i","Plasmodium berghei","PROTEIN KINASE","PF00069(Pkinase);PF13499(EF-hand_7)",7,"VAL A  71;ALA A  84;THR A 144;PHE A 146;GLY A 150;ASN A 195;LEU A 197","ANP A1634 (-4.1A);ANP A1634 (-3.6A);ANP A1634 (-4.6A);ANP A1634 (-4.8A);None; CA A 528 ( 3.0A);ANP A1634 (-4.4A)","0.69A","4wa9B-3q5iA:22.2","4wa9B-3q5iA:21.43"],["4WA9_B_AXIB9000_1","3tt0","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"VAL A 492;ALA A 512;LYS A 514;GLY A 567;ASN A 628;LEU A 630;ALA A 640","07J A   1 (-4.0A);07J A   1 (-3.5A);07J A   1 (-4.5A);07J A   1 (-3.7A);None;07J A   1 ( 4.4A);07J A   1 (-3.2A)","0.85A","4wa9B-3tt0A:31.1","4wa9B-3tt0A:38.86"],["4WA9_B_AXIB9000_1","3txo","Homo sapiens","PROTEIN KINASE C ETA TYPE","PF00069(Pkinase);PF00433(Pkinase_C)",7,"VAL A 369;ALA A 382;LYS A 384;PHE A 435;GLY A 439;LEU A 486;ALA A 496","07U A   1 (-4.8A);07U A   1 (-3.3A);07U A   1 (-3.0A);None;None;07U A   1 (-4.3A);07U A   1 ( 4.0A)","0.77A","4wa9B-3txoA:13.8","4wa9B-3txoA:25.07"],["4WA9_B_AXIB9000_1","3txo","Homo sapiens","PROTEIN KINASE C ETA TYPE","PF00069(Pkinase);PF00433(Pkinase_C)",7,"VAL A 369;ALA A 382;PHE A 435;GLY A 439;ASN A 484;LEU A 486;ALA A 496","07U A   1 (-4.8A);07U A   1 (-3.3A);None;None;None;07U A   1 (-4.3A);07U A   1 ( 4.0A)","0.78A","4wa9B-3txoA:13.8","4wa9B-3txoA:25.07"],["4WA9_B_AXIB9000_1","3vid","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"VAL A 848;ALA A 866;LYS A 868;PHE A 918;GLY A 922;ASN A1033;LEU A1035","4TT A2001 ( 4.5A);4TT A2001 (-3.5A);None;4TT A2001 (-4.5A);4TT A2001 (-3.7A);None;4TT A2001 (-4.8A)","0.75A","4wa9B-3vidA:30.3","4wa9B-3vidA:34.14"],["4WA9_B_AXIB9000_1","3wzd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"VAL A 848;ALA A 866;LYS A 868;PHE A 918;GLY A 922;ASN A1033;LEU A1035","LEV A1201 ( 4.9A);LEV A1201 (-3.5A);None;LEV A1201 (-4.7A);LEV A1201 (-3.6A);GOL A1210 (-3.6A);LEV A1201 (-4.8A)","0.87A","4wa9B-3wzdA:32.3","4wa9B-3wzdA:37.50"],["4WA9_B_AXIB9000_1","3zbf","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","PF07714(Pkinase_Tyr)",7,"VAL A1959;ALA A1978;LYS A1980;MET A2029;GLY A2032;ASN A2084;LEU A2086","None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);None;VGH A3000 (-3.5A);None;VGH A3000 (-4.3A)","0.99A","4wa9B-3zbfA:26.6","4wa9B-3zbfA:40.26"],["4WA9_B_AXIB9000_1","3zfx","Homo sapiens","EPHRIN TYPE-B RECEPTOR 1","PF07714(Pkinase_Tyr)",8,"VAL A 633;ALA A 649;THR A 697;PHE A 699;MET A 700;GLY A 703;ASN A 749;LEU A 751","None","0.64A","4wa9B-3zfxA:33.3","4wa9B-3zfxA:41.14"],["4WA9_B_AXIB9000_1","4aw5","Homo sapiens","EPHRIN TYPE-B RECEPTOR 4","PF07714(Pkinase_Tyr)",7,"VAL A 105;ALA A 121;LYS A 123;THR A 169;PHE A 171;MET A 172;ASN A 221","30K A1365 ( 4.6A);30K A1365 (-3.2A);30K A1365 (-3.8A);30K A1365 (-3.8A);30K A1365 (-4.4A);None;30K A1365 (-4.4A)","0.93A","4wa9B-4aw5A:32.4","4wa9B-4aw5A:38.36"],["4WA9_B_AXIB9000_1","4aw5","Homo sapiens","EPHRIN TYPE-B RECEPTOR 4","PF07714(Pkinase_Tyr)",8,"VAL A 105;ALA A 121;THR A 169;PHE A 171;MET A 172;GLY A 175;ASN A 221;LEU A 223","30K A1365 ( 4.6A);30K A1365 (-3.2A);30K A1365 (-3.8A);30K A1365 (-4.4A);None;30K A1365 (-3.5A);30K A1365 (-4.4A);30K A1365 (-4.5A)","0.67A","4wa9B-4aw5A:32.4","4wa9B-4aw5A:38.36"],["4WA9_B_AXIB9000_1","4bc6","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 10","PF00069(Pkinase)",8,"VAL A  50;ALA A  63;LYS A  65;PHE A 112;GLY A 116;ASN A 162;LEU A 164;ALA A 174","XZN A1317 ( 4.7A);XZN A1317 (-3.5A);XZN A1317 (-4.1A);XZN A1317 (-4.5A);XZN A1317 ( 3.7A);None;XZN A1317 (-4.7A);XZN A1317 ( 4.3A)","1.13A","4wa9B-4bc6A:22.2","4wa9B-4bc6A:29.58"],["4WA9_B_AXIB9000_1","4c02","Homo sapiens","ACTIVIN RECEPTOR TYPE-1","PF00069(Pkinase);PF08515(TGF_beta_GS)",7,"VAL A 222;ALA A 233;THR A 283;GLY A 289;ASN A 341;LEU A 343;ALA A 353","TAK A1507 (-4.7A);TAK A1507 (-3.3A);TAK A1507 (-3.6A);TAK A1507 (-3.5A);None;TAK A1507 (-4.7A);TAK A1507 ( 4.2A)","0.74A","4wa9B-4c02A:26.0","4wa9B-4c02A:27.59"],["4WA9_B_AXIB9000_1","4ckr","Homo sapiens","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","PF07714(Pkinase_Tyr)",9,"VAL A 624;ALA A 653;LYS A 655;THR A 701;MET A 704;GLY A 707;ASN A 771;LEU A 773;ALA A 783","DI1 A1000 (-4.8A);DI1 A1000 (-3.6A);DI1 A1000 (-3.9A);DI1 A1000 (-3.6A);None;None;None;DI1 A1000 (-4.5A);DI1 A1000 (-3.7A)","0.71A","4wa9B-4ckrA:29.8","4wa9B-4ckrA:37.77"],["4WA9_B_AXIB9000_1","4f0i","Homo sapiens","HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",7,"VAL A 523;ALA A 541;LYS A 543;MET A 591;GLY A 594;ASN A 654;LEU A 656","None","0.70A","4wa9B-4f0iA:24.6","4wa9B-4f0iA:36.86"],["4WA9_B_AXIB9000_1","4k11","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"VAL A 281;ALA A 293;MET A 341;GLY A 344;ASN A 391;LEU A 393;ALA A 403","0J9 A 601 (-4.4A);0J9 A 601 (-3.3A);None;0J9 A 601 ( 4.1A);None;0J9 A 601 (-4.5A);0J9 A 601 (-3.5A)","0.79A","4wa9B-4k11A:30.5","4wa9B-4k11A:35.94"],["4WA9_B_AXIB9000_1","4lgg","Gallus gallus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF07714(Pkinase_Tyr)",7,"VAL A 281;ALA A 293;MET A 341;GLY A 344;ASN A 391;LEU A 393;ALA A 403","VGG A 601 ( 3.5A);VGG A 601 (-3.5A);None;VGG A 601 ( 3.2A);None;VGG A 601 (-4.5A);VGG A 601 ( 4.2A)","0.77A","4wa9B-4lggA:29.9","4wa9B-4lggA:46.69"],["4WA9_B_AXIB9000_1","4m69","Mus musculus","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",7,"ALA A  49;THR A  95;PHE A  97;MET A  98;GLY A 101;LEU A 150;ALA A 160","ANP A 401 (-3.1A);ANP A 401 (-3.8A);ANP A 401 (-3.8A);None;None;ANP A 401 (-4.8A);None","0.85A","4wa9B-4m69A:24.4","4wa9B-4m69A:29.05"],["4WA9_B_AXIB9000_1","4m69","Mus musculus","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",7,"VAL A  36;ALA A  49;THR A  95;MET A  98;GLY A 101;LEU A 150;ALA A 160","ANP A 401 (-4.5A);ANP A 401 (-3.1A);ANP A 401 (-3.8A);None;None;ANP A 401 (-4.8A);None","0.78A","4wa9B-4m69A:24.4","4wa9B-4m69A:29.05"],["4WA9_B_AXIB9000_1","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",7,"VAL A  54;ALA A  67;LYS A  69;THR A 123;GLY A 128;ASN A 178;LEU A 180","None;SIN A 401 ( 3.7A);None;None;SIN A 401 (-3.5A);None;SIN A 401 ( 4.5A)","0.71A","4wa9B-4o38A:20.7","4wa9B-4o38A:25.29"],["4WA9_B_AXIB9000_1","4p2k","Homo sapiens","EPHRIN TYPE-A RECEPTOR 2","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"VAL A 627;ALA A 644;THR A 692;MET A 695;GLY A 698;ASN A 744;LEU A 746","None","0.85A","4wa9B-4p2kA:32.6","4wa9B-4p2kA:38.85"],["4WA9_B_AXIB9000_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",7,"VAL A  22;ALA A  35;LYS A  37;THR A  81;MET A  84;LEU A 136;ALA A 146","ACP A1264 (-4.7A);ACP A1264 (-2.9A);None;ACP A1264 (-4.5A);None;ACP A1264 ( 4.8A);None","0.82A","4wa9B-4ueuA:33.7","4wa9B-4ueuA:64.34"],["4WA9_B_AXIB9000_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",8,"VAL A  22;ALA A  35;THR A  81;MET A  84;GLY A  87;ASN A 134;LEU A 136;ALA A 146","ACP A1264 (-4.7A);ACP A1264 (-2.9A);ACP A1264 (-4.5A);None;ACP A1264 (-3.5A);None;ACP A1264 ( 4.8A);None","0.65A","4wa9B-4ueuA:33.7","4wa9B-4ueuA:64.34"],["4WA9_B_AXIB9000_1","4usf","Homo sapiens","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","PF00069(Pkinase)",7,"ALA A  61;PHE A 110;GLY A 114;ASN A 160;LEU A 162;ALA A 172;PHE A 174","6UI A 700 (-3.3A);6UI A 700 (-4.3A);6UI A 700 ( 4.2A);None;6UI A 700 (-4.2A);6UI A 700 ( 4.1A);None","1.31A","4wa9B-4usfA:18.0","4wa9B-4usfA:29.14"],["4WA9_B_AXIB9000_1","4usf","Homo sapiens","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","PF00069(Pkinase)",7,"VAL A  48;ALA A  61;PHE A 110;GLY A 114;ASN A 160;LEU A 162;ALA A 172","None;6UI A 700 (-3.3A);6UI A 700 (-4.3A);6UI A 700 ( 4.2A);None;6UI A 700 (-4.2A);6UI A 700 ( 4.1A)","1.04A","4wa9B-4usfA:18.0","4wa9B-4usfA:29.14"],["4WA9_B_AXIB9000_1","4wsq","Homo sapiens","AP2-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",7,"VAL A  60;ALA A  72;LYS A  74;PHE A 128;GLY A 132;ASN A 181;LEU A 183","KSA A 405 ( 4.9A);KSA A 405 (-3.2A);None;KSA A 405 (-4.8A);KSA A 405 (-3.5A);KSA A 405 (-4.0A);KSA A 405 (-4.6A)","0.78A","4wa9B-4wsqA:24.0","4wa9B-4wsqA:24.25"],["4WA9_B_AXIB9000_1","4xcu","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 4","PF07714(Pkinase_Tyr)",7,"VAL A 481;ALA A 501;LYS A 503;GLY A 556;ASN A 617;LEU A 619;ALA A 629","40M A1002 ( 4.5A);40M A1002 ( 4.1A);40M A1002 (-4.0A);40M A1002 ( 3.7A);None;40M A1002 (-4.5A);40M A1002 (-3.0A)","0.93A","4wa9B-4xcuA:31.5","4wa9B-4xcuA:40.00"],["4WA9_B_AXIB9000_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",9,"VAL B 275;ALA B 288;THR B 334;PHE B 336;MET B 337;GLY B 340;ASN B 387;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);None;1N1 B 601 (-3.5A);None;1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.48A","4wa9B-4xeyB:40.8","4wa9B-4xeyB:78.14"],["4WA9_B_AXIB9000_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",9,"VAL B 275;ALA B 288;THR B 334;PHE B 336;MET B 337;GLY B 340;LEU B 389;ALA B 399;PHE B 401","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A);None","1.09A","4wa9B-4xeyB:40.8","4wa9B-4xeyB:78.14"],["4WA9_B_AXIB9000_1","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",7,"VAL A 416;ALA A 428;THR A 474;MET A 477;GLY A 480;ASN A 526;LEU A 528","746 A 702 ( 4.3A);746 A 702 (-2.4A);746 A 702 (-3.7A);None;746 A 702 (-3.6A);746 A 702 (-2.8A);746 A 702 (-4.4A)","0.56A","4wa9B-4y93A:30.8","4wa9B-4y93A:29.48"],["4WA9_B_AXIB9000_1","4yff","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TNNI3K","PF07714(Pkinase_Tyr)",7,"VAL A 477;ALA A 488;LYS A 490;THR A 539;GLY A 545;LEU A 595;ALA A 605","None;4CV A 801 (-3.5A);4CV A 801 (-3.9A);4CV A 801 (-2.8A);4CV A 801 ( 4.0A);4CV A 801 (-4.4A);4CV A 801 ( 3.9A)","0.72A","4wa9B-4yffA:26.3","4wa9B-4yffA:28.66"],["4WA9_B_AXIB9000_1","5e8y","Homo sapiens","TGF-BETA RECEPTOR TYPE-2","PF07714(Pkinase_Tyr)",7,"VAL A 258;ALA A 275;LYS A 277;THR A 325;PHE A 327;GLY A 331;LEU A 386","STU A 601 (-4.0A);STU A 601 (-3.1A);STU A 601 (-2.4A);STU A 601 ( 3.7A);STU A 601 (-3.4A);STU A 601 (-3.5A);STU A 601 (-3.9A)","0.86A","4wa9B-5e8yA:19.8","4wa9B-5e8yA:27.66"],["4WA9_B_AXIB9000_1","5e8y","Homo sapiens","TGF-BETA RECEPTOR TYPE-2","PF07714(Pkinase_Tyr)",7,"VAL A 258;ALA A 275;THR A 325;PHE A 327;GLY A 331;ASN A 384;LEU A 386","STU A 601 (-4.0A);STU A 601 (-3.1A);STU A 601 ( 3.7A);STU A 601 (-3.4A);STU A 601 (-3.5A);STU A 601 ( 4.9A);STU A 601 (-3.9A)","0.63A","4wa9B-5e8yA:19.8","4wa9B-5e8yA:27.66"],["4WA9_B_AXIB9000_1","5iso","Homo sapiens","5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-2","PF00069(Pkinase);PF16579(AdenylateSensor)",7,"VAL A  30;ALA A  43;LYS A  45;GLY A  99;ASN A 144;LEU A 146;ALA A 156","STU A 601 (-4.8A);STU A 601 (-3.3A);STU A 601 ( 4.4A);STU A 601 ( 4.0A);STU A 601 (-4.3A);STU A 601 (-4.5A);STU A 601 (-3.5A)","0.77A","4wa9B-5isoA:25.1","4wa9B-5isoA:19.13"],["4WA9_B_AXIB9000_1","5j5t","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3","PF00069(Pkinase)",7,"VAL A  30;ALA A  43;LYS A  45;PHE A  92;GLY A  96;LEU A 143;ALA A 153","6G2 A 901 ( 4.9A);6G2 A 901 (-3.2A);6G2 A 901 ( 3.9A);6G2 A 901 (-4.1A);6G2 A 901 (-3.6A);6G2 A 901 (-4.7A);6G2 A 901 ( 4.2A)","0.69A","4wa9B-5j5tA:22.1","4wa9B-5j5tA:24.25"],["4WA9_B_AXIB9000_1","5j5t","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3","PF00069(Pkinase)",7,"VAL A  30;ALA A  43;PHE A  92;GLY A  96;ASN A 141;LEU A 143;ALA A 153","6G2 A 901 ( 4.9A);6G2 A 901 (-3.2A);6G2 A 901 (-4.1A);6G2 A 901 (-3.6A);None;6G2 A 901 (-4.7A);6G2 A 901 ( 4.2A)","0.62A","4wa9B-5j5tA:22.1","4wa9B-5j5tA:24.25"],["4WA9_B_AXIB9000_1","5l6o","Homo sapiens","EPHRIN TYPE-B RECEPTOR 3","PF07714(Pkinase_Tyr)",7,"ALA A 663;THR A 711;PHE A 713;MET A 714;ASN A 763;LEU A 765;PHE A 777","6P6 A1001 (-3.3A);6P6 A1001 (-3.5A);6P6 A1001 ( 4.5A);None;None;6P6 A1001 (-4.5A);DIO A1002 (-4.5A)","1.30A","4wa9B-5l6oA:31.4","4wa9B-5l6oA:38.67"],["4WA9_B_AXIB9000_1","5l6o","Homo sapiens","EPHRIN TYPE-B RECEPTOR 3","PF07714(Pkinase_Tyr)",7,"VAL A 647;ALA A 663;LYS A 665;PHE A 713;MET A 714;ASN A 763;LEU A 765","None;6P6 A1001 (-3.3A);None;6P6 A1001 ( 4.5A);None;None;6P6 A1001 (-4.5A)","0.78A","4wa9B-5l6oA:31.4","4wa9B-5l6oA:38.67"],["4WA9_B_AXIB9000_1","5l6o","Homo sapiens","EPHRIN TYPE-B RECEPTOR 3","PF07714(Pkinase_Tyr)",7,"VAL A 647;ALA A 663;THR A 711;PHE A 713;MET A 714;ASN A 763;LEU A 765","None;6P6 A1001 (-3.3A);6P6 A1001 (-3.5A);6P6 A1001 ( 4.5A);None;None;6P6 A1001 (-4.5A)","0.62A","4wa9B-5l6oA:31.4","4wa9B-5l6oA:38.67"],["4WA9_B_AXIB9000_1","5lpy","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",7,"VAL A 897;ALA A 909;LYS A 911;PHE A 958;MET A 959;GLY A 962;LEU A1016","ATP A1200 ( 4.5A);ATP A1200 (-3.5A);ATP A1200 (-3.8A);ATP A1200 ( 4.0A);None;ATP A1200 ( 4.0A);ATP A1200 (-4.6A)","0.63A","4wa9B-5lpyA:24.7","4wa9B-5lpyA:28.62"],["4WA9_B_AXIB9000_1","5lpy","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",7,"VAL A 897;ALA A 909;PHE A 958;MET A 959;GLY A 962;ASN A1014;LEU A1016","ATP A1200 ( 4.5A);ATP A1200 (-3.5A);ATP A1200 ( 4.0A);None;ATP A1200 ( 4.0A);ATP A1200 (-3.6A);ATP A1200 (-4.6A)","0.53A","4wa9B-5lpyA:24.7","4wa9B-5lpyA:28.62"],["4WA9_B_AXIB9000_1","5lpz","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",7,"VAL A 897;ALA A 909;PHE A 958;MET A 959;GLY A 962;ASN A1014;LEU A1016","ADP A1200 (-4.4A);ADP A1200 (-3.5A);ADP A1200 (-4.1A);None;ADP A1200 ( 4.0A);ADP A1200 (-3.6A);ADP A1200 (-4.7A)","0.46A","4wa9B-5lpzA:24.8","4wa9B-5lpzA:29.71"],["4WA9_B_AXIB9000_1","5td2","Homo sapiens","TYROSINE-PROTEIN KINASE MER","PF07714(Pkinase_Tyr)",7,"VAL A 601;ALA A 617;PHE A 673;MET A 674;GLY A 677;ASN A 728;ALA A 740","7AE A1000 ( 4.9A);7AE A1000 (-3.3A);7AE A1000 (-4.1A);None;7AE A1000 ( 3.7A);7AE A1000 (-4.7A);7AE A1000 ( 3.7A)","0.61A","4wa9B-5td2A:29.0","4wa9B-5td2A:42.38"],["4WA9_B_AXIB9000_1","5tos","Arabidopsis thaliana","SERINE\/THREONINE-PROTEIN KINASE BIK1","no annotation",7,"VAL A  81;ALA A 103;LYS A 105;MET A 153;GLY A 156;ASN A 207;LEU A 209","None","1.09A","4wa9B-5tosA:18.2","4wa9B-5tosA:12.59"],["4WA9_B_AXIB9000_1","5tos","Arabidopsis thaliana","SERINE\/THREONINE-PROTEIN KINASE BIK1","no annotation",7,"VAL A  81;ALA A 103;PHE A 152;MET A 153;GLY A 156;ASN A 207;LEU A 209","None","0.78A","4wa9B-5tosA:18.2","4wa9B-5tosA:12.59"],["4WA9_B_AXIB9000_1","5u6b","Homo sapiens","TYROSINE-PROTEIN KINASE RECEPTOR UFO","PF07714(Pkinase_Tyr)",7,"VAL A 550;ALA A 565;LYS A 567;PHE A 622;MET A 623;GLY A 626;ALA A 689","7YS A9001 (-4.2A);7YS A9001 (-3.3A);None;7YS A9001 (-4.3A);7YS A9001 (-4.7A);7YS A9001 (-3.4A);7YS A9001 (-3.4A)","0.77A","4wa9B-5u6bA:30.2","4wa9B-5u6bA:43.85"],["4WA9_B_AXIB9000_1","5u6b","Homo sapiens","TYROSINE-PROTEIN KINASE RECEPTOR UFO","PF07714(Pkinase_Tyr)",7,"VAL A 550;ALA A 565;PHE A 622;MET A 623;GLY A 626;ASN A 677;ALA A 689","7YS A9001 (-4.2A);7YS A9001 (-3.3A);7YS A9001 (-4.3A);7YS A9001 (-4.7A);7YS A9001 (-3.4A);None;7YS A9001 (-3.4A)","0.78A","4wa9B-5u6bA:30.2","4wa9B-5u6bA:43.85"],["4WA9_B_AXIB9000_1","5w5j","Homo sapiens","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","no annotation",8,"VAL A  32;ALA A  45;THR A  95;MET A  98;GLY A 101;ASN A 151;LEU A 153;ALA A 163","9WS A 401 ( 4.6A);9WS A 401 (-3.3A);9WS A 401 (-3.2A);None;9WS A 401 ( 4.3A);None;9WS A 401 (-4.6A);9WS A 401 ( 4.0A)","0.64A","4wa9B-5w5jA:24.2","4wa9B-5w5jA:27.91"],["4WA9_B_AXIB9000_1","5xzw","Saccharomyces cerevisiae","SERINE\/THREONINE-PROTEIN KINASE RAD53","no annotation",7,"VAL A 212;ALA A 225;LYS A 227;PHE A 275;GLY A 279;ASN A 324;LEU A 326","None","0.88A","4wa9B-5xzwA:19.3","4wa9B-5xzwA:22.47"],["4WA9_B_AXIB9000_1","6cmj","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2","no annotation",7,"VAL A 179;ALA A 192;LYS A 194;GLY A 273;ASN A 317;LEU A 319;ALA A 329","F6J A 501 (-4.6A);F6J A 501 (-3.4A);F6J A 501 (-2.9A);F6J A 501 ( 3.7A);F6J A 501 ( 4.7A);F6J A 501 (-4.5A);F6J A 501 ( 4.0A)","0.73A","4wa9B-6cmjA:24.4","4wa9B-6cmjA:14.49"],["4WA9_B_AXIB9000_1","6cz4","Homo sapiens","PROTEIN-TYROSINE KINASE 6","no annotation",7,"VAL A 205;ALA A 217;THR A 264;MET A 267;GLY A 270;ASN A 317;LEU A 319","FKY A9001 ( 4.6A);FKY A9001 (-3.3A);FKY A9001 (-3.0A);None;FKY A9001 (-3.3A);None;FKY A9001 ( 4.9A)","0.94A","4wa9B-6cz4A:29.3","4wa9B-6cz4A:18.41"],["4WA9_B_AXIB9000_1","6fdy","-","-","no annotation",7,"VAL U  28;ALA U  42;LYS U  44;PHE U  93;GLY U  97;LEU U 144;ALA U 156","DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.0A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.98A","4wa9B-6fdyU:23.8","4wa9B-6fdyU:undetectable"],["4WA9_B_AXIB9000_1","6fdy","-","-","no annotation",7,"VAL U  28;ALA U  42;PHE U  93;GLY U  97;ASN U 142;LEU U 144;ALA U 156","DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.4A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.5A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.82A","4wa9B-6fdyU:23.8","4wa9B-6fdyU:undetectable"]]